Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug-platform company developing novel therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting the results of its recent phase 2/3 Alzheimer’s study. The study was designed to evaluate Buntanetap, the company’s lead drug candidate. According to the report, key findings indicate that Buntanetap showed statistically significant efficacy and safety in the treatment of both carriers and noncarriers of Apolipoprotein E4 (APOE4), a genetic cause of AD. The company has scheduled an investor call for today at 4:30 p.m. ET to provide more detailed information and outline future development plans for Buntanetap. Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43. “Encouraged by these results, Annovis Bio is planning an 18-month phase 3 trial focusing on biomarker-positive early-AD patients,” stated the company in the press release. “This trial aims to further validate Buntanetap’s efficacy and safety profile and will be conducted under the guidance of the FDA.”

To view the call, visit

To view the full press release, visit

About Annovis Bio Inc.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

This entry was posted in Small Cap News. Bookmark the permalink.

Comments are closed.